Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.
Use this IBRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IBRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IBRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Immunitybio Inc even when a live quote feed is slow.
Latest cached year on this hub. Full IBRX income, balance, and cash tables.